<DOC>
	<DOCNO>NCT00003708</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness temozolomide treat patient advance solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , tolerability , maximum tolerate dose , dose limit toxicity temozolomide patient advance solid malignancy . II . Characterize single- multiple-dose pharmacokinetics temozolomide follow oral administration patient . III . Determine antitumor activity temozolomide patient . OUTLINE : This open label , dose escalation study . Patients receive oral temozolomide day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat escalate dos temozolomide . The maximum tolerate dose define dose 1 6 patient experience dose limit toxicity ( DLT ) course 1 2 , least 2 patient experience DLT next high dose level . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven solid malignancy curative therapy exist Glioblastoma eligible follow criterion meet : Stable performance status Stable symptom At least 4 week stable dose dexamethasone CNS metastases allow progression new edema present Measurable evaluable disease No acute chronic leukemia multiple myeloma No known bone marrow involvement tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 3 time upper limit normal ( ULN ) ( 5 time ULN due liver metastasis ) Renal : Creatinine great 1.5 mg/dL Other : No malabsorption syndrome due prior surgery , gastrointestinal disease , unknown reason No concurrent nonmalignant systemic disease No active uncontrolled infection No frequent vomit medical condition could interfere oral medication uptake ( e.g. , partial bowel obstruction , bowel resection , partial intestinal bypass , external biliary diversion ) No prior concurrent malignancy sit except carcinoma situ cervix adequately treat basal squamous cell skin cancer HIV negative No AIDSrelated illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No prior allogeneic , syngeneic , autologous bone marrow transplantation No prior peripheral blood stem cell transplantation No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy least 25 % bone marrow ( include pelvic irradiation ) recover No concurrent radiotherapy Surgery : Prior major gastrointestinal surgery allow ( e.g. , Whipple procedure ) Other : At least 4 week since prior investigational therapy At least 24 hour since prior alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>